- Home
- MULN vs SNSE Comparison
MULN vs SNSE Comparison
Compare MULN & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- SNSE
- Stock Information
- Founded
- MULN 2014
- SNSE 2005
- Country
- MULN United States
- SNSE United States
- Employees
- MULN N/A
- SNSE N/A
- Industry
- MULN Auto Manufacturing
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- MULN Consumer Discretionary
- SNSE Health Care
- Exchange
- MULN Nasdaq
- SNSE Nasdaq
- Market Cap
- MULN 12.2M
- SNSE 12.5M
- IPO Year
- MULN N/A
- SNSE 2021
- Fundamental
- Price
- MULN $4.01
- SNSE $0.45
- Analyst Decision
- MULN
- SNSE Strong Buy
- Analyst Count
- MULN 0
- SNSE 3
- Target Price
- MULN N/A
- SNSE $4.33
- AVG Volume (30 Days)
- MULN 497.1K
- SNSE 168.7K
- Earning Date
- MULN 02-19-2025
- SNSE 03-03-2025
- Dividend Yield
- MULN N/A
- SNSE N/A
- EPS Growth
- MULN N/A
- SNSE N/A
- EPS
- MULN N/A
- SNSE N/A
- Revenue
- MULN $4,014,807.00
- SNSE N/A
- Revenue This Year
- MULN N/A
- SNSE N/A
- Revenue Next Year
- MULN N/A
- SNSE N/A
- P/E Ratio
- MULN N/A
- SNSE N/A
- Revenue Growth
- MULN 996.94
- SNSE N/A
- 52 Week Low
- MULN $3.96
- SNSE $0.38
- 52 Week High
- MULN $47,100.00
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- MULN 22.53
- SNSE 38.52
- Support Level
- MULN $10.80
- SNSE $0.44
- Resistance Level
- MULN $21.00
- SNSE $0.49
- Average True Range (ATR)
- MULN 2.78
- SNSE 0.04
- MACD
- MULN 1.42
- SNSE -0.00
- Stochastic Oscillator
- MULN 0.29
- SNSE 10.73
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.